Business
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
STAFFORD, Texas--(BUSINESS WIRE)-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":" STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.\n\nCEO Snehal Patel will make a presentation that will be available on demand beginning on September 13th to conference attendees. In addition, the Company will be participating in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.\n\nH.C. Wainwright 23rd Annual Global Investment Conference \n\nH.C. Wainwright’s Global Investment Conference will include leading industry keynote speakers and presenting companies, investor one-on-one meetings, networking opportunities with attendees, and an evening of entertainment. For more information, please visit the conference website at: https://hcwevents.com/annualconference/\n\nAbout Breast Cancer and HER2/neu Positivity\n\nOne in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 282,000 new breast cancer patients and 3.8 million breast cancer survivors in 2021. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.\n\nAbout Greenwich LifeSciences, Inc.\n\nGreenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse ...